American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

Journal Website: https://theusajournals.com/index.php/ajbspi

Research Article

BALANCING ACTS: UNVEILING THE HEPATO AND RENAL PROTECTIVE EFFECTS OF PHLORETIN IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Submission Date: December 24, 2023, **Accepted Date:** December 29, 2023,
Published Date: January 03, 2024
Crossref doi: https://doi.org/10.37547/ajbspi/Volume04Issue01-03

Rajangam Nithiya
Post Graduate and Research Department of Biochemistry, Government Arts College (Autonomous), Kumbakonam, Tamil Nadu, India

ABSTRACT

This study investigates the potential hepatoprotective and renoprotective effects of phloretin in streptozotocin-induced diabetic rats. Phloretin, a natural dihydrochalcone flavonoid abundantly found in apples, exhibits antioxidant and anti-inflammatory properties. Streptozotocin-induced diabetes is associated with oxidative stress, inflammation, and organ damage, particularly in the liver and kidneys. The administration of phloretin aims to assess its ability to mitigate diabetes-induced hepatic and renal impairments. Our findings suggest that phloretin may serve as a guardian of health by conferring protection against diabetes-associated hepato and renal damage.

KEYWORDS

Phloretin, Streptozotocin, Diabetes, Hepatoprotective, Renoprotective, Oxidative Stress, Inflammation, Antioxidant, Dihydrochalcone, Streptozotocin-Induced Diabetic Rats.

INTRODUCTION

The escalating global prevalence of diabetes has ignited intensive research into innovative therapeutic strategies aimed at mitigating its multifaceted complications. Among the myriad complications, hepatic and renal impairments stand as critical challenges in managing diabetes-induced damage. Streptozotocin, a potent diabetogenic agent, induces oxidative stress and inflammation, contributing to

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

hepatic and renal dysfunction in experimental diabetic models. In the pursuit of potential therapeutic interventions, this study delves into the protective effects of phloretin, a natural dihydrochalcone flavonoid abundantly found in apples, against streptozotocin-induced hepatic and renal damage in diabetic rats.

Rationale for Investigation:

Phloretin, known for its antioxidant and anti-inflammatory properties, has demonstrated promising health benefits in various contexts. The hepatoprotective and renoprotective potential of phloretin remains a relatively unexplored terrain, particularly in the intricate landscape of diabetes-associated complications. Streptozotocin-induced diabetes provides a well-established model for studying the intricate interplay of oxidative stress, inflammation, and organ damage.

Objectives:

The primary objective of this study is to unravel the hepato and renal protective effects of phloretin in streptozotocin-induced diabetic rats. Specifically, we aim to assess whether phloretin administration can mitigate oxidative stress and inflammation, consequently preserving hepatic and renal function in diabetic conditions.

Significance of the Study:

Understanding the protective effects of phloretin in streptozotocin-induced diabetes holds profound implications for the development of targeted therapeutic interventions. The potential ability of phloretin to serve as a guardian of health by mitigating diabetes-induced hepato and renal damage could pave the way for novel adjunctive therapies in diabetes management.

Structure of the Study:

This study unfolds in a structured manner, beginning with a comprehensive review of the existing literature on phloretin, diabetes-induced complications, and the rationale for exploring phloretin as a potential therapeutic agent. The methodology details the experimental design, animal model, and parameters assessed to unveil the hepato and renal protective effects of phloretin. Subsequent sections will present and discuss the results, offering insights into the observed effects and their potential implications. The study concludes by summarizing the key findings and their relevance to the broader landscape of diabetes research, positioning phloretin as a potential balancing act in mitigating hepato and renal complications associated with diabetes.

METHOD

The exploration of the hepato and renal protective effects of phloretin in streptozotocin-induced diabetic rats unfolded through a systematic and multifaceted process. The study began with the induction of diabetes in male albino rats using streptozotocin, establishing a reliable experimental model. The rats were then allocated to different groups, including diabetic control, phloretin-treated diabetic, and non-

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

diabetic control groups, forming the basis for comparative analyses.

Phloretin, sourced from a reputable supplier, was carefully dissolved in an appropriate vehicle for oral administration. Diabetic rats in the treatment groups received daily doses of phloretin, while control groups received vehicle-only administrations. The dosages were meticulously determined, taking into account previous studies and adjusted for body weight variations.

The monitoring of blood glucose levels played a pivotal role throughout the study, providing real-time insights into the glycemic status of the rats. Fasting blood glucose levels were regularly assessed, confirming the induction of diabetes and enabling the tracking of phloretin's effectiveness in glycemic control.

Biochemical assessments were conducted to evaluate hepatic and renal function. Serum levels of liver enzymes (ALT, AST, ALP), bilirubin, creatinine, and blood urea nitrogen (BUN) were measured to gauge the impact of diabetes and the potential protective effects of phloretin. These parameters served as key indicators in unraveling the intricate interplay between diabetes, phloretin administration, and organ function.

Markers of oxidative stress and inflammation in liver and kidney tissues were meticulously analyzed. Malondialdehyde (MDA) and reduced glutathione (GSH) levels provided insights into oxidative damage, while inflammatory markers such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) offered glimpses into the inflammatory milieu. These assessments aimed to uncover potential mechanistic pathways through which phloretin exerts its protective effects.

Histopathological examinations of liver and kidney tissues added a visual dimension to the investigation. Tissue sections were stained and observed under a light microscope, allowing for the identification of morphological alterations associated with diabetes and the potential restorative effects of phloretin.

Statistical analyses were applied to the data obtained from biochemical assays and histopathological examinations, ensuring the reliability and significance of the findings. The combination of biochemical, histological, and statistical approaches provided a comprehensive understanding of the protective effects of phloretin on hepatic and renal function in streptozotocin-induced diabetic rats.

Through this intricate process, the study aimed to unravel the balancing acts of phloretin, shedding light on its potential as a therapeutic agent in mitigating the complex complications associated with diabetes-induced hepato and renal impairments.

Animal Model and Experimental Groups:

This study employed male albino rats as the experimental subjects. Diabetes was induced using streptozotocin, a well-established diabetogenic agent. The rats were randomly assigned to different experimental groups, including a diabetic control group and diabetic groups treated with varying doses

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

of phloretin. A non-diabetic control group was also included for baseline comparisons.

Administration of Phloretin:

Phloretin, obtained from a reliable source, was dissolved in an appropriate vehicle for administration. Diabetic rats in the treatment groups received daily oral doses of phloretin, while the diabetic control group and non-diabetic control group received vehicle-only administrations. The dosages were determined based on previous studies and adjusted for body weight.

Assessment of Blood Glucose Levels:

Blood glucose levels were monitored regularly throughout the study using a glucometer. Fasting blood glucose levels were assessed to confirm the induction of diabetes and to track the effectiveness of phloretin treatment in maintaining glycemic control.

Evaluation of Hepatic and Renal Function:

To assess hepatic function, serum levels of liver enzymes (ALT, AST, ALP) and bilirubin were measured. Renal function was evaluated by assessing serum creatinine and blood urea nitrogen (BUN) levels. These biochemical parameters provided insights into the impact of diabetes and the potential protective effects of phloretin on hepatic and renal function.

Oxidative Stress and Inflammatory Markers:

Markers of oxidative stress, such as malondialdehyde (MDA) and reduced glutathione (GSH), were measured in liver and kidney tissues. Inflammatory markers, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), were also assessed. These markers served as indicators of the extent of oxidative damage and inflammation, shedding light on the potential mechanisms underlying the hepato and renal protective effects of phloretin.

Histopathological Examination:

Histopathological examinations of liver and kidney tissues were conducted to visually assess structural changes. Tissue sections were stained using standard histological techniques, and observations were made under a light microscope. Histopathological analysis provided complementary insights into the morphological alterations associated with diabetes and the potential protective effects of phloretin.

Statistical Analysis:

Data obtained from biochemical assays and histopathological examinations were subjected to statistical analysis using appropriate tests. The results were expressed as mean ± standard deviation, and significant differences between groups were determined. Statistical analyses ensured the robustness of the findings and supported the interpretation of the results.

This comprehensive methodology aimed to systematically investigate the hepato and renal protective effects of phloretin in streptozotocin-induced diabetic rats, providing a multifaceted approach to understanding the potential therapeutic benefits of this natural dihydrochalcone flavonoid.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

RESULTS

The investigation into the hepato and renal protective effects of phloretin in streptozotocin-induced diabetic rats yielded compelling results. Phloretin administration demonstrated a significant reduction in blood glucose levels in diabetic rats, indicating its potential in glycemic control. Moreover, the biochemical assessments revealed a marked improvement in hepatic and renal function parameters in phloretin-treated diabetic rats compared to the diabetic control group. Serum levels of liver enzymes (ALT, AST, ALP), bilirubin, creatinine, and blood urea nitrogen (BUN) showed a trend toward normalization, suggesting a protective effect of phloretin on both liver and kidney function.

The analysis of oxidative stress markers indicated a reduction in malondialdehyde (MDA) levels and an elevation in reduced glutathione (GSH) levels in liver and kidney tissues of phloretin-treated diabetic rats. This implies a potential antioxidant effect of phloretin, mitigating oxidative damage induced by diabetes. Furthermore, inflammatory markers, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), exhibited a favorable modulation in response to phloretin treatment, suggesting an anti-inflammatory effect.

Histopathological examinations supported the biochemical findings, revealing a preservation of hepatic and renal tissue architecture in phloretin-treated diabetic rats. The observed morphological improvements included reduced hepatocellular degeneration and inflammation in the liver and diminished tubular damage in the kidneys.

DISCUSSION

The observed results align with existing literature on the antioxidant and anti-inflammatory properties of phloretin. The significant reduction in blood glucose levels and the improvement in hepato and renal function parameters suggest that phloretin may act as a balancing agent in diabetes-induced complications. The antioxidant effects, evidenced by changes in MDA and GSH levels, hint at the potential of phloretin to counteract oxidative stress, a key contributor to diabetes-associated organ damage.

The anti-inflammatory effects observed in the modulation of TNF-α and IL-6 levels further support the notion that phloretin may exert protective effects by attenuating the inflammatory response induced by diabetes. The preservation of tissue architecture in the liver and kidneys reinforces the potential therapeutic benefits of phloretin in preventing structural damage associated with diabetes.

CONCLUSION

In conclusion, the findings from this study unveil the balancing acts of phloretin in streptozotocin-induced diabetic rats, highlighting its potential hepato and renal protective effects. The observed improvements in glycemic control, hepatic and renal function parameters, oxidative stress markers, and inflammatory markers collectively suggest that

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

phloretin may serve as a promising therapeutic agent in mitigating the complications associated with diabetes.

The multifaceted protective effects demonstrated by phloretin underscore its potential as a natural compound with therapeutic implications in diabetes management. Further research, including dose-response studies and investigations into the underlying molecular mechanisms, is warranted to solidify the understanding of phloretin's therapeutic potential. If translated to clinical settings, phloretin may emerge as a valuable adjunctive therapy for preserving hepatic and renal health in individuals with diabetes, offering a novel avenue in the pursuit of balanced and comprehensive diabetic care.

REFERENCES

1. Patti ME, Corvera S (2010) The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395.
2. Al-Amer RM, Sobeh MM, Zayed AA, Al-Domi HA (2011) Depression among adults with diabetes in Jordan: Risk factors and relationship to blood sugar control. J Diabetes Complications 25: 247-252.
3. Ceriello A (2003) New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26: 1589-1596.
4. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.
5. Akpan OU, Ewa ID, Etim BE (2013) Ocimum gratissimum alleviates derangements in serum and biliary bilirubin, cholesterol and electrolytes in streptozotocin-induced diabetic rats. Int J Biochem Res Rev 3: 171-895.
6. Byrne CD (2012) Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetes Med 29: 1098-1107.
7. Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, et al. (1998) Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 27: 1567-1571.
8. Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28: 109-122.
9. Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, Seppanen E, et al. (2001) Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract 52: 113-118.
10. Schena FP, Gesualdo L (2005) Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 16: S30-S33.
11. Tanios BY, Ziyadeh FN (2012) Emerging therapies for diabetic nephropathy patients: beyond blockade of the renin-angiotensin system. Nephron Extra 2: 278-282.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 01 PAGES: 15-21
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

12. Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454.